(Q37728856)

22 August 2017

1 reference

title

Oncogenic mutations as predictive factors in colorectal cancer (English)

1 reference

22 August 2017

1 reference

3

1 reference

22 August 2017

A Lièvre

1

1 reference

22 August 2017

H Blons

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

12 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

29

1 reference

22 August 2017

issue

21

1 reference

22 August 2017

page(s)

3033-3043

1 reference

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Genetic pathways to colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Somatic mutations of EGFR in colorectal cancers and glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA cancer mutations display gender and tissue specificity patterns.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

A genetic model for colorectal tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Functional analysis of PIK3CA gene mutations in human colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Cetuximab for the treatment of colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

EGFR FISH in colorectal cancer: what is the current reality?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Colorectal cancer: mutations in a signalling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

RAF/RAS oncogenes and mismatch-repair status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

High frequency of mutations of the PIK3CA gene in human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Ras, PI(3)K and mTOR signalling controls tumour cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PTEN gene mutations in colorectal cancers displaying microsatellite instability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

BRAF mutation predicts sensitivity to MEK inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Moyamoya disease and moyamoya syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Molecular determinants of cetuximab efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

The prevalence of PIK3CA mutations in gastric and colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

The guanine nucleotide-binding switch in three dimensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.89

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.89

1 reference

22 August 2017

1 reference